Complement C4 Antibody Market By Product Type (Diagnostic Tests, Reagents, Research Antibodies); By Application (Autoimmune Disease Diagnosis, Drug Discovery, Clinical Research); By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations, Diagnostic Laboratories); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Complement C4 Antibody Market: Autoimmune Testing, Infection Workups, and Tissue Research Sustain Reagent Demand

The Global Complement C4 Antibody Market was valued at approximately USD 545.5 million in 2025 and is projected to reach nearly USD 1.00 billion by 2032, expanding at a CAGR of 9.1%, according to Strategic Market Research.

 

Complement C4 antibodies are laboratory tools rather than medicines. Clinical laboratories use C4-specific antibodies and antisera to measure Complement Component 4 in serum or plasma. Pathologists use anti-C4d antibodies to examine complement deposition in tissue biopsies, particularly after organ transplantation. Research laboratories purchase antibodies against C4A, C4B, C4b, C4c, and C4d for Western blot, immunohistochemistry, ELISA, immunofluorescence, and related studies.

 

The market covers C4 antibodies, C4 antisera, antibody-based reagent cartridges, C4d tissue-staining antibodies, ELISA antibody pairs, conjugated antibodies, calibrators, controls, and other related assay components. It does not include laboratory service fees, the total value of diagnostic analyzers, unrelated complement therapies, or products from C4 Therapeutics, which operates in oncology-focused targeted protein degradation rather than complement diagnostics.

 

A Tool-Driven Market Supported by Clinical and Research Workflows

Commercial demand comes from the need to determine whether C4 is being consumed, deposited in tissue, genetically underproduced, or elevated during inflammation. C4 supports the classical and lectin complement pathways and contributes to the clearance of microbes, immune complexes, and damaged cells. Once activated, it produces fragments including C4a, C4b, C4c, and C4d, creating separate antibody requirements. C4A and C4B share more than 99% sequence identity, but C4A reacts more readily with protein-containing immune complexes while C4B has stronger affinity for microbial and cellular surfaces. This makes isotype and fragment specificity commercially important.

The market remains dominated by diagnostics and research. Direct C4 inhibition is still experimental. Preclinical work with C4b-specific nanobodies shows that selective pathway inhibition is possible, but no established commercial market for approved anti-C4 therapeutic antibodies has formed. Drugs targeting C1s, C3, C5, factor B, or other complement proteins should therefore not be counted as Complement C4 antibody revenue.

 

Automated Serum Testing Produces the Most Predictable Revenue

Serum C4 measurement is the largest recurring use. Hospital and reference laboratories order C4 tests when evaluating systemic lupus erythematosus, hereditary angioedema, immune-complex disease, vasculitis, glomerulonephritis, recurrent infections, complement deficiencies, hepatitis, cirrhosis, and selected transplant complications. South Tees Hospitals lists immune-complex disorders, infectious diseases, vasculitis, glomerulonephritis, and immunodeficiency associated with recurrent infections among the principal indications for combined C3 and C4 testing.

The U.S. FDA classifies complement-component immunological test systems under 21 CFR 866.5240. Complement C4 antigen, antiserum, and control products use product code DBI and are regulated as Class II devices, supporting a regulated market for assay-specific reagents, calibrators, and controls.

An FDA review of a Beckman Coulter system noted that the reagent kits included two cartridges, each supporting 100 tests, with polyclonal antibodies directed against C3 or C4. The C4 assay had an analytical range of 5 to 120 mg/dL, intra-assay precision of 1.32% to 2.37%, and total precision of 1.68% to 3.09%. After validation on an installed chemistry platform, one biomarker can create recurring consumable revenue through repeated reagent purchases.

Roche supplies Tina-quant Complement C4 version 2, Beckman Coulter sells OSR6160 reagent for AU platforms, and Siemens Healthineers supports C4 measurement across Atellica, Dimension, ADVIA Chemistry, and nephelometry systems. Laboratories that validate one system usually reorder compatible reagents, calibrators, and controls, giving installed-platform suppliers stronger customer retention than stand-alone research-antibody vendors.

The supplied USD 459 million and 38.2% North American figure appears to cover a broader C3/C4 testing category, analyzer-linked reagents, or laboratory services. Applying it directly to the narrower USD 545.5 million antibody market would overstate regional concentration. SMR therefore estimates North America at approximately 40% of global Complement C4 antibody revenue.

 

Autoimmune Disease Burden Expands the Addressable Testing Population

Autoimmune disease creates the broadest clinical and research demand pool. NIH identifies more than 140 autoimmune diseases affecting an estimated 23.5 million to 50 million Americans. About 25% of affected patients have two or more autoimmune conditions, and annual U.S. healthcare costs exceed USD 100 billion. Not all these patients require C4 testing, but the scale of the autoimmune population supports complement research, differential diagnosis, and repeat monitoring.

Rheumatoid arthritis adds a large chronic inflammatory research population. WHO estimated that 18 million people worldwide were living with rheumatoid arthritis in 2019; approximately 70% were women, 55% were older than 55 years, and 13 million had moderate or severe disease. C4 is not routinely low in uncomplicated rheumatoid arthritis, but complement assays and antibodies are used in research involving rheumatoid vasculitis, immune-complex activity, and systemic inflammation.

Lupus remains the strongest direct demand source. The CDC estimates that approximately 204,000 Americans have classified SLE, including about 184,000 females and 20,000 males. Approximately nine out of ten people with lupus are women. Broader advocacy estimates of 1.5 million Americans and 5 million people globally include several forms of lupus and should not be presented as confirmed SLE prevalence.

C3 and C4 may fall during active immune-complex disease, so clinicians compare serial C4 results with symptoms, kidney function, urinalysis, anti-double-stranded DNA antibodies, and other markers. Lupus nephritis may affect approximately 20% to 65% of people with SLE, depending on population and diagnostic criteria. Repeat testing during suspected flares, treatment changes, pregnancy, and kidney monitoring creates a more durable reagent opportunity than one-time diagnosis.

 

Recurrent Infections and Immunodeficiency Support Specialist Testing

Complement testing is also used when patients have frequent, severe, prolonged, or unusual infections. The CDC recognizes more than 400 types of primary immunodeficiency, and people with these disorders are more likely to experience repeated ear or sinus infections, pneumonia, bronchitis, meningitis, skin infections, and infections that require intravenous antibiotics or hospitalization. A CDC genomics review estimated that primary immunodeficiencies affect approximately one in 1,200 U.S. births.

C4 deficiency is only a small part of this wider group, but its connection with infection is commercially relevant. Research has associated C4A deficiency with recurrent respiratory infections and C4B deficiency with bacteremia, severe infections, and bacterial meningitis. The Frontiers review also notes that deficiency of either C4A or C4B increases susceptibility to infection.

Complete deficiency of both C4A and C4B is exceptionally rare. Published literature identified 28 individuals from 19 families; 22 of the 28, or 78.6%, developed SLE or a lupus-like disease. This supports the supplied 75% to 80% autoimmune-association range when applied specifically to complete deficiency rather than ordinary partial gene variation.

Hereditary angioedema caused by C1 inhibitor deficiency affects about one person in 50,000, suggesting roughly 6,000 U.S. patients. Serum C4 is commonly assessed with C1 inhibitor antigen and functional activity. The segment is small but commercially stable because testing is concentrated in immunology laboratories, allergy clinics, rare-disease centres, and family screening.

 

Low and High C4 Create Different Diagnostic and Research Needs

Common C4 reference intervals include 15 to 45 mg/dL, 14 to 48 mg/dL, and 20 to 50 mg/dL. South Tees reports an adult interval of 20 to 50 mg/dL and notes that acute-phase values can reach twice the upper limit. Very low concentrations below 1 mg/dL may occur in active immune-complex disease, cryoglobulinemia, or C1 inhibitor deficiency.

Low C4 can reflect active SLE, lupus nephritis, vasculitis, glomerulonephritis, liver disease, severe infection, cryoglobulinemia, or inherited deficiency. Low C3 with low C4 supports classical-pathway activation, while very low C4 with relatively preserved C3 can prompt investigation for hereditary or acquired C1 inhibitor deficiency. Serial changes are generally more informative than one isolated result.

High C4 is less specific. As an acute-phase protein, C4 can increase during infection, inflammation, tissue injury, metabolic stress, and recovery. Chronic inflammatory populations create adjacent research demand: metabolic syndrome has affected about 34% of U.S. adults in historical estimates and 20% to 25% of adults globally, while newer evidence places U.S. ulcerative colitis prevalence near 1.25 million and sarcoidosis near 150,000 to 200,000. These populations should not be counted as routine C4-testing cohorts, but they support biomarker studies examining complement activation and chronic inflammation.

 

Western Blot, IHC, and ELISA Broaden Research-Reagent Demand

Western blot is used to confirm C4 protein expression, molecular weight, and antibody specificity in cell lysates, serum, or tissue extracts. Thermo Fisher’s Complement C4 polyclonal antibody PA5-144311 is listed for Western blot at dilutions from 1:500 to 1:5,000 and produced an observed band near 193 kDa in validation data. The same product is listed for paraffin IHC at 1:500 to 1:1,000 and for ELISA on an assay-dependent basis, showing how one antibody can serve three major research workflows.

Immunohistochemistry has particular commercial value in tissue research and transplant pathology because it localizes C4 or C4d deposition rather than measuring only circulating concentration. Thermo Fisher’s 16D2 monoclonal antibody is reported across five applications—frozen-tissue IHC, immunoprecipitation, ELISA, immunofluorescence, and Western blot—with suggested 1:50 dilutions for Western blot, frozen IHC, ELISA, and immunoprecipitation. Thermo Fisher’s catalog page listed 12 Complement C4 antibodies, illustrating the fragmented, application-specific nature of the research market.

ELISA supports quantitative C4 research in serum and plasma. Bio-Techne’s human C4 colorimetric ELISA kit reports an assay range of 0.313 to 5 µg/mL, sensitivity of 0.25 µg/mL, intra-assay variation below 4.4%, inter-assay variation below 8.7%, and recovery of 94%, although the company notes that values are lot dependent. These measurable performance indicators influence purchasing because laboratories compare sensitivity, precision, recovery, sample requirements, and reproducibility rather than relying only on antibody concentration.

 

C4d Tissue Staining Creates a High-Value Transplant Segment

Anti-C4d antibodies identify complement deposition in tissue and are used with microvascular inflammation, graft injury, donor-specific antibodies, and Banff classification criteria. C4d is clinically important but is not an independent definitive diagnosis because C4d-negative antibody-mediated rejection can occur.

The United States performed a record 27,660 adult kidney transplants in 2024, up from 27,351 in 2023. Preliminary OPTN data counted 27,759 total kidney transplants and 48,149 transplants across all organs, reflecting different reporting scopes. Globally, the transplant observatory recorded 110,467 kidney transplants in 2024. A larger recipient base increases the number of patients who may later require biopsies for graft dysfunction or suspected rejection, supporting a smaller-volume but higher-value C4d antibody segment.

 

Competition Centres on Validation and Platform Compatibility

Cell Signaling Technology offers a recombinant rabbit monoclonal antibody against endogenous C4A and C4B. Thermo Fisher supplies C4 antibodies across Western blot, IHC, ELISA, immunoprecipitation, and immunofluorescence. Bio-Techne offers ELISA kits and C4B/C4d antibodies, while Bio-Rad, Abcam, Proteintech, and Agilent compete through fragment-specific and pathology products.

Polyclonal antibodies remain relevant in turbidimetric and nephelometric assays because multiple-epitope recognition can improve immune-complex formation. Recombinant monoclonal antibodies are gaining importance in research and pathology because they provide more consistent long-term supply and lower lot-to-lot variation.

Roche Diagnostics, Siemens Healthineers, Beckman Coulter, and Thermo Fisher hold strong positions in clinical testing through analyzer-compatible reagents and recurring consumables. Bio-Rad, Cell Signaling Technology, Abcam, Bio-Techne, Proteintech, and Agilent compete through clone quality, recombinant production, tissue validation, species coverage, fragment specificity, and publication history.

 

Regional Analysis: North America Leads While Asia-Pacific Expands

North America is expected to retain approximately 40% of global revenue through laboratory automation, FDA-regulated assays, a large autoimmune-testing population, more than 27,000 annual kidney transplants, and major antibody suppliers. Europe remains established through national laboratory systems, autoimmune services, hereditary angioedema testing, transplant centres, and complement research.

Asia-Pacific is expected to expand fastest through 2032 as hospitals automate immunoprotein testing, transplant activity rises, and local antibody manufacturing improves. International suppliers are likely to retain an advantage in regulated analyzer-specific assays, while regional manufacturers can gain share in research antibodies and ELISA kits.

 

Market Outlook: Diagnostic Reagents Remain the Revenue Foundation

Automated serum testing will remain the largest revenue source through 2032. Lupus provides the strongest repeat-monitoring population, recurrent infection and immunodeficiency workups support specialist demand, and transplant pathology sustains a lower-volume but higher-value C4d segment.

Western blot, IHC, and ELISA will broaden research sales as laboratories investigate C4 expression, tissue deposition, chronic inflammation, kidney biomarkers, genetic copy-number variation, and complement-pathway drug targets. Suppliers that document assay-specific dilution, sensitivity, precision, recovery, and tissue performance will be better positioned than vendors offering broadly reactive antibodies with limited validation.

The market will remain primarily tool-driven rather than therapeutic. Companies combining regulated diagnostic reagents, analyzer compatibility, reproducible antibodies, fragment-specific validation, and trusted C4d pathology products are best positioned to capture the projected USD 1.00 billion market by 2032.

 

Complement C4 Antibody Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 545.5 Million
Revenue Forecast in 2032	USD 1.00 Billion
Overall Growth Rate	CAGR of 9.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	C4 Antibodies, C4 Antisera, C4d Tissue-Staining Antibodies, ELISA Antibody Pairs, Conjugated Antibodies, Antibody-Based Reagent Cartridges, Calibrators and Controls, Other Related Assay Components
By Application	Autoimmune Disease Diagnosis, Complement Testing, Transplant Rejection Monitoring, Immunodeficiency Evaluation, Infection Workups, Drug Discovery, Clinical Research, Tissue Research and Pathology Studies
By End User	Diagnostic Laboratories, Hospitals and Healthcare Institutions, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations (CROs), Pathology Laboratories
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising autoimmune disease testing demand, increasing lupus and immune-complex disorder monitoring, growth in transplant pathology applications, expansion of laboratory automation, rising demand for validated research antibodies, and increasing complement pathway research activity
Customization Option	Available upon request